RegisterLogin

AT7519

CAT: 0804-HY-50940-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-50940-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
CAS Number
[844442-38-2]
Product Name Alternative
AT7519M
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/at7519.html
Purity
99.69
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(NC1=CNN=C1C(NC2CCNCC2)=O)C3=C(Cl)C=CC=C3Cl
Molecular Formula
C16H17Cl2N5O2
Molecular Weight
382.24
Precautions
H315, H319, H320
References & Citations
[1]Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29 (16) :2325-36.|[2]Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.|[3]Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9 (4) :920-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9
Citation 01
Adv Sci (Weinh) . 2024 Mar;11 (11) :e2305260.|bioRxiv. 2024 September 07.|bioRxiv. 2025 Nov 17.|Dev Biol. 2024 Apr:508:93-106.|EMBO Mol Med. 2025 Nov 26.|Exp Eye Res. 2023 Feb:227:109391.|FASEB J. 2024 Apr 30;38 (8) :e23628.|Glycobiology. 2022 Aug 18;32 (9) :751-759.|Harvard Medical School LINCS LIBRARY|Oncogene. 2023 Nov;42 (47) :3503-3513.|PLoS One. 2025 Jun 17;20 (6) :e0324443.|RNA Biol. 2021 Nov 12;18 (sup2) :722-729.|Sci Rep. 2021 Mar 8;11 (1) :5374.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Cell Chem Biol. 2018 Feb 15;25 (2) :135-142.e5.|Harvard Medical School LINCS LIBRARY

Related Products

CatalogName
HY-124603-01AT791

Alternative Products

CatalogName
T6205-01AT7519
GW4564-10mgAT7519 hydrochloride
MBS5757085AT7519 trifluoroacetate
A10093-5AT7519 5mg
bs-83812C-01AT7519 HCl
A10093-100AT7519 100mg
A10093-10AT7519 10mg

Popular Products